Immunic Inc. (IMUX), a clinical-stage biotechnology company developing small-molecule therapies for chronic inflammatory and autoimmune diseases, is gearing up for a key catalyst - and it all revolves around its lead drug candidate, Vidofludimus calcium.
Vidofludimus calcium is a small-molecule therapy designed to target multiple pathways driving neurodegeneration, including inflammation, viral activity, and direct neuronal damage, in the treatment of Multiple sclerosis.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.